Latest Insider Transactions at Radius Health, Inc. (RDUS)
This section provides a real-time view of insider transactions for Radius Health, Inc. (RDUS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Radius Health, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Radius Health, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2022
|
Machelle Sanders Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,500
-100.0%
|
$55,000
$10.0 P/Share
|
|
Aug 15
2022
|
Chhaya Shah Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
94,645
-100.0%
|
$946,450
$10.0 P/Share
|
|
Aug 15
2022
|
Andrew C. Von Eschenbach Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,500
-100.0%
|
$55,000
$10.0 P/Share
|
|
Aug 15
2022
|
Sean Murphy Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,500
-100.0%
|
$55,000
$10.0 P/Share
|
|
Aug 15
2022
|
Elizabeth Messersmith Senior Vice President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
70,000
-100.0%
|
$700,000
$10.0 P/Share
|
|
Aug 15
2022
|
G. Kelly Martin CEO and President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
75,000
-100.0%
|
$750,000
$10.0 P/Share
|
|
Aug 15
2022
|
Owen Hughes Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
21,650
-100.0%
|
$216,500
$10.0 P/Share
|
|
Aug 15
2022
|
Danielle Holtschlag Vice President, Sales |
SELL
Sale (or disposition) back to the issuer
|
Direct |
25,000
-100.0%
|
$250,000
$10.0 P/Share
|
|
Aug 15
2022
|
Jean Pierre Garnier Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,500
-100.0%
|
$55,000
$10.0 P/Share
|
|
Aug 15
2022
|
Jean Pierre Garnier Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
26,800
-82.97%
|
$268,000
$10.0 P/Share
|
|
Aug 15
2022
|
Cathy Friedman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
26,800
-100.0%
|
$268,000
$10.0 P/Share
|
|
Aug 15
2022
|
Willard H Dere Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,895
-100.0%
|
$18,950
$10.0 P/Share
|
|
Aug 15
2022
|
Willard H Dere Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
21,300
-91.83%
|
$213,000
$10.0 P/Share
|
|
Aug 11
2022
|
Target N V Biotech > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
8,733,538
-100.0%
|
$87,335,380
$10.0 P/Share
|
|
Aug 11
2022
|
Rubric Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,678,954
+16.27%
|
$16,789,540
$10.07 P/Share
|
|
Aug 10
2022
|
Rubric Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,012
+0.06%
|
$40,120
$10.07 P/Share
|
|
May 18
2022
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
477,824
+5.19%
|
$2,389,120
$5.57 P/Share
|
|
Mar 15
2022
|
Mark William Conley VP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Feb 21
2022
|
G. Kelly Martin CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
1,035,000
+50.0%
|
-
|
|
Jan 14
2022
|
Willard H Dere Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+19.17%
|
-
|
|
Jan 14
2022
|
Jean Pierre Garnier Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+17.03%
|
-
|
|
Jan 14
2022
|
Danielle Holtschlag Vice President, Sales |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Jan 14
2022
|
Cathy Friedman Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+17.03%
|
-
|
|
Jan 14
2022
|
Sean Murphy Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+33.33%
|
-
|
|
Jan 14
2022
|
Steven Helwig Principal Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+32.43%
|
-
|
|
Jan 14
2022
|
Owen Hughes Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+20.26%
|
-
|
|
Jan 14
2022
|
Machelle Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+50.0%
|
-
|
|
Jan 14
2022
|
Andrew C. Von Eschenbach Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+50.0%
|
-
|
|
Jan 14
2022
|
Chhaya Shah Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+40.72%
|
-
|
|
Jan 06
2022
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
300,000
+3.51%
|
$1,800,000
$6.31 P/Share
|
|
Jan 05
2022
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
250,000
+3.05%
|
$1,500,000
$6.3 P/Share
|
|
Dec 16
2021
|
Rubric Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
146,685
+2.06%
|
$1,026,795
$7.07 P/Share
|
|
Dec 15
2021
|
Rubric Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
180,744
+2.58%
|
$1,084,464
$6.77 P/Share
|
|
Dec 14
2021
|
Rubric Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
94,103
+1.4%
|
$564,618
$6.81 P/Share
|
|
Dec 13
2021
|
Rubric Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
187,391
+2.79%
|
$1,311,737
$7.08 P/Share
|
|
Dec 10
2021
|
Rubric Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
768,171
+10.79%
|
$5,377,197
$7.17 P/Share
|
|
Dec 09
2021
|
Rubric Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
264,644
+4.53%
|
$1,852,508
$7.58 P/Share
|
|
Dec 08
2021
|
Rubric Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
560,691
+9.54%
|
$4,485,528
$8.02 P/Share
|
|
Sep 29
2021
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
100,000
+1.28%
|
$1,200,000
$12.95 P/Share
|
|
Sep 22
2021
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
150,000
+1.93%
|
$1,800,000
$12.28 P/Share
|
|
Aug 24
2021
|
Steven Helwig Principal Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,125
+19.75%
|
-
|
|
May 17
2021
|
Chhaya Shah Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+25.22%
|
-
|
|
Mar 05
2021
|
James George Chopas Principal Finance Accounting |
SELL
Open market or private sale
|
Direct |
370
-5.23%
|
$7,400
$20.88 P/Share
|
|
Feb 25
2021
|
Sal Grausso Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,322
-10.15%
|
$23,796
$18.93 P/Share
|
|
Feb 22
2021
|
Owen Hughes Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+25.4%
|
-
|
|
Feb 22
2021
|
Cathy Friedman Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+20.52%
|
-
|
|
Feb 22
2021
|
Jean Pierre Garnier Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+20.52%
|
-
|
|
Feb 22
2021
|
Willard H Dere Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+23.71%
|
-
|
|
Feb 22
2021
|
Sean Murphy Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+50.0%
|
-
|
|
Nov 05
2020
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
100,000
+1.32%
|
$1,400,000
$14.26 P/Share
|